WINTON GROUP Ltd Takes Position in InMode Ltd. $INMD

WINTON GROUP Ltd acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 41,700 shares of the healthcare company’s stock, valued at approximately $613,000.

Several other institutional investors have also modified their holdings of INMD. Leonteq Securities AG bought a new position in shares of InMode during the 4th quarter valued at about $26,000. Advisory Services Network LLC bought a new stake in InMode in the 3rd quarter valued at approximately $37,000. Basepoint Wealth LLC bought a new stake in InMode in the 4th quarter valued at approximately $39,000. Parallel Advisors LLC lifted its stake in InMode by 113.3% in the 4th quarter. Parallel Advisors LLC now owns 4,318 shares of the healthcare company’s stock valued at $63,000 after acquiring an additional 2,294 shares in the last quarter. Finally, Rothschild Investment LLC bought a new stake in InMode in the 3rd quarter valued at approximately $85,000. Institutional investors own 68.04% of the company’s stock.

InMode Stock Down 0.7%

Shares of InMode stock opened at $13.47 on Thursday. InMode Ltd. has a 12-month low of $12.72 and a 12-month high of $16.74. The stock has a market cap of $853.46 million, a P/E ratio of 9.90 and a beta of 1.94. The business’s 50 day moving average is $13.93 and its 200-day moving average is $14.17.

InMode (NASDAQ:INMD) last posted its earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.05). The business had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. InMode had a return on equity of 13.47% and a net margin of 23.27%.The firm’s revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.31 earnings per share.

Analyst Ratings Changes

Several equities research analysts have commented on INMD shares. Robert W. Baird cut their target price on InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Barclays set a $19.00 target price on InMode and gave the company an “overweight” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $16.00.

InMode Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.